Institutions
1 Immune-mediated Inflammatory Skin Disease research group, IMIBIC/Reina Sofía University Hospital/University of Córdoba, Menendez Pidal Ave, 14004 Córdoba, Spain.
2 Department of Dermatology, Reina Sofía University Hospital, Menendez Pidal Ave, 14004 Córdoba, Spain.
3 Agencia de Evaluación de Tecnologías Sanitarias (AETSA), Consejería de Salud, Junta de Andalucía, 41020 Sevilla, Spain.
4 Department of Pharmacy, Reina Sofía University Hospital, Menendez Pidal Ave, 14004 Córdoba, Spain.
Correspondence
Juan Ruano
Department of Dermatology
Reina Sofía University Hospital
Menendez Pidal Ave, 14004 Córdoba, Spain
Conflict of interest
FG-G has received honoraria for research from Pfizer, and for lecturing from AbbVie, Janssen-Cilag and Novartis; JR has received honoraria for lecturing and grants for research from Pfizer, honoraria for lecturing from Janssen-Cilag and Novartis, and other financial benefits from AbbVie and Novartis. MA-L, JR, FG-G, JG-M, and BI-T are members of the Cochrane Bias Methods Group and Skin Group. JLS-C, PA-M, BM-L, PJC-F, and MG-P have no disclosures.
Funding sources
This work was supported, in part, by project ICI1400136 to JR, integrated into the National Plan of R+D+I 2008-2011 and co-financed by the ISCIII-Subdirección General de Evaluación and European Regional Development Fund (ERDF), by project PIN-0316-2017 of the Consejería de Salud, Junta de Andalucía (Spain) to JR, and by grant PP13/009 of Plan Propio de movilidad para investigadores del Instituto Maimonides de Investigacion Biomédica de Córdoba (IMIBIC). No funding was received from any pharmaceutical company.